Only the new beginning of VAP quality control
Critical Care volume 27, Article number: 107 (2023)
We would like to thank to Dr Wang and colleagues for their interest and comments about our article . Before we respond to their comments, we have to explain that the data from the National Clinical Improvement System were uploaded by hospitals and were the descriptive data of the hospital profile rather than individual cases, which was mentioned as one of the limitations in our article . Therefore, the information of other factors such as ventilator days, age, gender, and comorbidities of every case were not included in the database. As the number of cases diagnosed and died of VAP among different hospitals were counting data, which were approximately following Poisson distribution, Poisson regression model was better to answer the questions such as what factors can influence the VAP incidence rate and mortality in this case.
Regarding the first question about the ventilator days, it is the fact that patient transfer between hospitals is very common. As the VAP incidence rate is used as one of the ICU quality control indicators, it is defined as the number of cases diagnosing VAP divided by the ventilator days during the same period in the ICU. The ventilator days of the patients transferred from other hospital with endotracheal intubation before admission were calculated in the previous hospitals.
The authors mentioned the heterogeneity of different specialized ICU and different hospital levels. First, as the data were collected by the China-National Critical Care Quality Control Center (China-NCCQC), although the ICUs in specialized hospitals such as Gynecologic and Obstetric hospital were included, specialized ICUs such as Respiratory ICU in general hospital were not included. As the doctors in specialized ICU received less training on nosocomial infection and were allocated with less resource, VAP incidence rate and mortality may be worse in these ICUs . Although it is generally believed that tertiary hospitals are usually more adequately staffed and equipped compared to secondary hospitals, which may lead to a lower rate of nosocomial infections, it is not the case at least for VAP . Considering the heterogeneity of development between different regions, the level of hospital may not be the unique standard to estimate the quality. For example, the ICUs in secondary hospitals from high GDP level area may be better than these in tertiary hospitals from low GDP level area.
We are glad to find that our research can raise the attention on VAP in ICU specialists, and this study was only the beginning of the VAP quality control. New research based on individual cases is on the way, and we hope the results could bring us more satisfactory answers to all those questions.
Availability of data and materials
Wang M, Huang L, Huang X. Letter to the Editor regarding “Effect of ICU quality control indicators on VAP incidence rate and mortality: a retrospective study of 1267 hospitals in China.” Crit Care. 2023;27(1):30.
Ding X, Ma X, Gao S, Su L, Shan G, Hu Y, Chen J, Ma D, Zhang F, Zhu W, et al. Effect of ICU quality control indicators on VAP incidence rate and mortality: a retrospective study of 1267 hospitals in China. Crit Care. 2022;26(1):405.
Liu YN, Cao B, Wang H, Chen LA, She DY, Zhao TM, Liang ZX, Sun TY, Li YM, Tong ZH, et al. Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35(10):739–46.
Li Z, Ma X, Gao S, Li Q, Luo H, Sun J, Du W, Su L, Wang L, Zhang Q, et al. Association between hospital and ICU structural factors and patient outcomes in China: a secondary analysis of the National Clinical Improvement System Data in 2019. Crit Care. 2022;26(1):24.
This study is supported by National High Level Hospital Clinical Research Funding (2022-PUMCH-B-115), CAMS Innovation Fund for Medical Sciences (CIFMS) from Chinese Academy of Medical Sciences (2021-I2M-1-062); National Key R&D Program of China, Ministry of Science and Technology of the People’s Republic of China (2021YFC2500801); Beijing Municipal Natural Science Foundation (M21019); The 2020 CMB Open Competition Program (No. 20-381).
Ethical approval and consent for participants
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ding, X., Ma, X. & Zhou, X. Only the new beginning of VAP quality control. Crit Care 27, 107 (2023). https://doi.org/10.1186/s13054-023-04358-0